目的:研究贲门腺癌(gastric cardia adenocarcinoma,GCA)中分泌型卷曲相关蛋白4(secreted frizzled related protein4,SFRP4)及SFRP5基因启动子区甲基化状态与贲门腺癌发生发展的关系。方法:采用甲基化特异性PCR(methylation specific P...目的:研究贲门腺癌(gastric cardia adenocarcinoma,GCA)中分泌型卷曲相关蛋白4(secreted frizzled related protein4,SFRP4)及SFRP5基因启动子区甲基化状态与贲门腺癌发生发展的关系。方法:采用甲基化特异性PCR(methylation specific PCR,MSP)方法检测94例GCA组织及47例相应癌旁正常组织中SFRP4和SFRP5基因的甲基化情况,并分析其与临床病理特征之间的关系。结果:94例GCA组织中SFRP4基因甲基化率为68.1%(64/94),显著高于癌旁正常组织中的甲基化发生率8.5%(4/47)(P<0.01);SFRP5基因在贲门腺癌组织中的甲基化发生率为79.8%(75/94),显著高于癌旁正常组织中的甲基化发生率12.8%(16/47)(P<0.01)。SFRP4基因在高、中分化腺癌组甲基化发生率为35%(14/40),显著低于低分化腺癌组的发生率92.6%(50/54)(P<0.01);SFRP4基因在无淋巴结转移组的甲基化发生率为60.5%(23/38),低于有淋巴结转移组73.2%(41/56),但其差异无统计学意义(P>0.05)。SFRP5基因在低分化腺癌组甲基化发生率为85.1%(46/54),高于高、中分化腺癌组甲基化发生率72.5%(29/40),但其差异无统计学意义(P>0.05);SFRP5基因甲基化发生率在无淋巴结转移组为65.8%(25/38),显著低于有淋巴结转移组89.3%(50/56)(P<0.05)。57例贲门腺癌组织中SFRP4和SFRP5基因同时发生甲基化者,高、中分化18例,低分化39例,两者间的差异具有统计学意义(P<0.05)。结论:SFRP4和SFRP5基因可能参与了贲门腺癌的发生,SFRP4,SFRP5基因的高甲基化状态与贲门腺癌的恶性行为有关。展开更多
目的研究人表皮生长因子受体2(HER-2)、Ki-67、基质金属蛋白酶-9(MMP-9)的表达与脑膜瘤肿瘤组织病理分级的关系,探讨其临床病理学意义。方法选取脑膜瘤手术切除标本33份,采用免疫组化法(IHC)检测石蜡包埋组织标本中HER-2、Ki-67、MMP-9...目的研究人表皮生长因子受体2(HER-2)、Ki-67、基质金属蛋白酶-9(MMP-9)的表达与脑膜瘤肿瘤组织病理分级的关系,探讨其临床病理学意义。方法选取脑膜瘤手术切除标本33份,采用免疫组化法(IHC)检测石蜡包埋组织标本中HER-2、Ki-67、MMP-9蛋白的表达情况,采用原位杂交方法(ISH)检测脑膜瘤石蜡包埋组织标本中HER-2、MMP-9编码的m RNA(HER-2 m RNA、MMP-9 m RNA)的表达情况,并用图象分析法进行形态学定量。结果恶性组和良性组HER-2、Ki-67、MMP-9蛋白的表达差异均有统计学意义(P<0.05)。良性复发组和良性非复发组的MMP-9 m RNA、HER-2 m RNA的表达差异有统计学意义(P<0.05)。结论 HER-2、Ki-67、MMP-9在脑膜瘤的表达与病理分级呈正相关,很可能是良恶性脑膜瘤鉴别诊断中有辅助作用的指标之一。HER-2、MMP-9在脑膜瘤的表达可能与脑膜瘤复发有关。HER-2及MMP-9较高表达可能与复发的良性脑膜瘤恶变有关。展开更多
Objective:To explore the efficacy of Lianhua Qingwen Capsule(莲花清瘟胶囊)on upper respiratory tract infection,to understand the impact of Lianhua Qingwen Capsule(莲花清瘟胶囊)on the treatment outcome of upper respira...Objective:To explore the efficacy of Lianhua Qingwen Capsule(莲花清瘟胶囊)on upper respiratory tract infection,to understand the impact of Lianhua Qingwen Capsule(莲花清瘟胶囊)on the treatment outcome of upper respiratory tract infection,and provide reference for rational clinical drug use.Methods:The HIS database based on 18 large third-grade class-A hospitals was selected to match 1:1 for upper respiratory tract infection patients using and without Lianhua Qingwen Capsule(莲花清瘟胶囊)according to certain standards.The recombination of treatment outcome as"recovery"and"improvement"in the database was defined as effective treatment,"ineffectiveness","death"and"other"as ineffectivetreatment populations,and the effectiveness of treatment outcomes in the remerged 2 groups was compared by propensity score method.Results:After matching,454 cases were in both the patients treated by(experimental group)and without(control group)Lianhua Qingwen Capsule(莲花清瘟胶囊).Analysis was performed by three Logistic regression methods,all showing regression coefficients greater than 0 and statistically significant differences(P<0.05).Conclusion:Patients with upper respiratory tract infection treated by Lianhua Qingwen Capsule(莲花清瘟胶囊)are more effective than that without Lianhua Qingwen Capsule(莲花清瘟胶囊),it can improve the clinical efficacy of patients with upper respiratory tract infection。展开更多
文摘目的:研究贲门腺癌(gastric cardia adenocarcinoma,GCA)中分泌型卷曲相关蛋白4(secreted frizzled related protein4,SFRP4)及SFRP5基因启动子区甲基化状态与贲门腺癌发生发展的关系。方法:采用甲基化特异性PCR(methylation specific PCR,MSP)方法检测94例GCA组织及47例相应癌旁正常组织中SFRP4和SFRP5基因的甲基化情况,并分析其与临床病理特征之间的关系。结果:94例GCA组织中SFRP4基因甲基化率为68.1%(64/94),显著高于癌旁正常组织中的甲基化发生率8.5%(4/47)(P<0.01);SFRP5基因在贲门腺癌组织中的甲基化发生率为79.8%(75/94),显著高于癌旁正常组织中的甲基化发生率12.8%(16/47)(P<0.01)。SFRP4基因在高、中分化腺癌组甲基化发生率为35%(14/40),显著低于低分化腺癌组的发生率92.6%(50/54)(P<0.01);SFRP4基因在无淋巴结转移组的甲基化发生率为60.5%(23/38),低于有淋巴结转移组73.2%(41/56),但其差异无统计学意义(P>0.05)。SFRP5基因在低分化腺癌组甲基化发生率为85.1%(46/54),高于高、中分化腺癌组甲基化发生率72.5%(29/40),但其差异无统计学意义(P>0.05);SFRP5基因甲基化发生率在无淋巴结转移组为65.8%(25/38),显著低于有淋巴结转移组89.3%(50/56)(P<0.05)。57例贲门腺癌组织中SFRP4和SFRP5基因同时发生甲基化者,高、中分化18例,低分化39例,两者间的差异具有统计学意义(P<0.05)。结论:SFRP4和SFRP5基因可能参与了贲门腺癌的发生,SFRP4,SFRP5基因的高甲基化状态与贲门腺癌的恶性行为有关。
文摘目的研究人表皮生长因子受体2(HER-2)、Ki-67、基质金属蛋白酶-9(MMP-9)的表达与脑膜瘤肿瘤组织病理分级的关系,探讨其临床病理学意义。方法选取脑膜瘤手术切除标本33份,采用免疫组化法(IHC)检测石蜡包埋组织标本中HER-2、Ki-67、MMP-9蛋白的表达情况,采用原位杂交方法(ISH)检测脑膜瘤石蜡包埋组织标本中HER-2、MMP-9编码的m RNA(HER-2 m RNA、MMP-9 m RNA)的表达情况,并用图象分析法进行形态学定量。结果恶性组和良性组HER-2、Ki-67、MMP-9蛋白的表达差异均有统计学意义(P<0.05)。良性复发组和良性非复发组的MMP-9 m RNA、HER-2 m RNA的表达差异有统计学意义(P<0.05)。结论 HER-2、Ki-67、MMP-9在脑膜瘤的表达与病理分级呈正相关,很可能是良恶性脑膜瘤鉴别诊断中有辅助作用的指标之一。HER-2、MMP-9在脑膜瘤的表达可能与脑膜瘤复发有关。HER-2及MMP-9较高表达可能与复发的良性脑膜瘤恶变有关。
基金China Academy of Chinese Medical Sciences Project approval:Science and technology innovation project of China Academy of Chinese Medical Sciences(ci2021a00702)approval:National key R&D plan"demonstration study on evidence-based evaluation and effect mechanism of ten large varieties of Chinese patent medicines and classic famous prescriptions in the treatment of major diseases after listing(2018yfc1707400)。
文摘Objective:To explore the efficacy of Lianhua Qingwen Capsule(莲花清瘟胶囊)on upper respiratory tract infection,to understand the impact of Lianhua Qingwen Capsule(莲花清瘟胶囊)on the treatment outcome of upper respiratory tract infection,and provide reference for rational clinical drug use.Methods:The HIS database based on 18 large third-grade class-A hospitals was selected to match 1:1 for upper respiratory tract infection patients using and without Lianhua Qingwen Capsule(莲花清瘟胶囊)according to certain standards.The recombination of treatment outcome as"recovery"and"improvement"in the database was defined as effective treatment,"ineffectiveness","death"and"other"as ineffectivetreatment populations,and the effectiveness of treatment outcomes in the remerged 2 groups was compared by propensity score method.Results:After matching,454 cases were in both the patients treated by(experimental group)and without(control group)Lianhua Qingwen Capsule(莲花清瘟胶囊).Analysis was performed by three Logistic regression methods,all showing regression coefficients greater than 0 and statistically significant differences(P<0.05).Conclusion:Patients with upper respiratory tract infection treated by Lianhua Qingwen Capsule(莲花清瘟胶囊)are more effective than that without Lianhua Qingwen Capsule(莲花清瘟胶囊),it can improve the clinical efficacy of patients with upper respiratory tract infection。